alexa Trans-9-Tetrahydrocannabinol-Like Discriminative-Stimulus Effects of Gabapentin in Cannabis Users | OMICS International
ISSN: 2329-6488
Journal of Alcoholism & Drug Dependence
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Trans-9-Tetrahydrocannabinol-Like Discriminative-Stimulus Effects of Gabapentin in Cannabis Users

Takato Hiranita*

Division of Neurotoxicology, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration (FDA), USA

Corresponding Author:
Takato Hiranita
Division of Neurotoxicology,
National Center for Toxicological Research (NCTR),
U.S. Food and Drug Administration (FDA),
3900 NCTR Road, Jefferson, AR 72079-9501, USA
E-mail: [email protected]

Received date: February 01, 2016 Accepted date: February 05, 2016 Published date: February 10, 2016

Citation: Hiranita T (2016) (−)-Trans-Δ9-Tetrahydrocannabinol-Like Discriminative-Stimulus Effects of Gabapentin in Cannabis Users. J Alcohol Drug Depend 4:e129. doi: 10.4172/2329-6488.1000e129

Copyright: © 2016 Hiranita T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Alcoholism & Drug Dependence


recent study by Dr. Joshua Lile and his colleagues demonstrated the capability of gabapentin to produce marijuana-like effects in humans. The finding is unexpected since the primary binding site of gabapentin is not thought to be any of the cannabinoid receptor subtypes. Gabapentin (Neurontin®) (Figure 1) is an FDA-approved medication for the treatment of epilepsy and neuropathic pain and several cases of its off-label use are also known. Several case reports have indicated gabapentin misuse/abuse [1-4] but the in vivo pharmacology and abuse potential of gabapentin have not yet been directly characterized. Thus, there is a clear need to characterize the in vivo pharmacology of gabapentin including its abuse potential.


Figure 1: Chemical structures of gabapentin, γ-aminobutyric acid (GABA), pregabalin and three branched-chain γ-amino acids.

In contrast to the in vivo assessment, the in vitro pharmacology of gabapentin has relatively been characterized. Gabapentin is a structural analogue of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) and 3 branched-chain γ-amino acids (L-isoleucine, Lleucine, and L-methionine) (Figure 1). Despite its structural similarity to GABA and these branched-chain γ-amino acids, several studies using radio ligand binding assays have reported low, if any, affinity of gabapentin (3-cyclohexyl-GABA) for GABA receptor subtypes (no inhibition at up to 1,000,000 nM) [5,6] and low, if any, potency to inhibit the uptake of [3H]-GABA (Ki value: 50,000 nM) [7] or [3H]- leucine (Ki value: 30,000 nM) [8].

In marked contrast to GABA receptor subtypes, several in vivo studies on [3H] gabapentin-binding sites have found a 26,300-fold higher affinity of gabapentin for auxiliary α2δ (α2δ-1 and α2δ-2) subunits on voltage-dependent calcium (Ca2+) channels (VDCCs) [9,10] in cerebral cortices of rats [5] and mice [11] (Kd values: 38 and 23 nM, respectively). Consistent with their structural similarity to gabapentin, several compounds (Figure 1) have been shown to be high-affinity ligands at the [3H] gabapentin-binding site. These include pregabalin [12] and the three branched-chain γ-amino acids (Lisoleucine, L-leucine, and L-methionine) [5] (IC50 values: 50-80 nM). GABA, however, has at least a 7,630-fold lower affinity for the [3H] gabapentin binding site in vivo (IC50 value: 610,000 nM) [5]. Based on the results from these studies using [3H] gabapentin, it is not surprising that gabapentin can influence a VDCC-mediated effect [13].

mDrug discrimination procedures have high human predictive validity with respect to the subjective effects of various test articles across pharmacological classes and have served as the gold standards for characterizing drug pharmacology in vivo because of their high pharmacological specificity [14-17]. Assessment of the capacity of gabapentin to induce a discriminative-stimulus (DS) in drug naïve subjects has not been reported. Interestingly, several L-VDCC blockers (nifedipine and verapamil) by themselves have been demonstrated to condition place preference in drug naïve rats using a placeconditioning procedure [18]. Considering the potential of gabapentin to serve as a functional L-VDCC antagonist [13,19,20], gabapentin alone at an appropriate dose and treatment time may exert an in vivo action indicative of its abuse potential.

Several studies using drug discrimination procedures have assessed the capacity of gabapentin or pregabalin to substitute for various psychoactive compounds from different pharmacological classes [21-26]. Among them is a double-blind, placebo-controlled, clinical study that found gabapentin capable of full substitution for the cannabinoid CB1/2 receptor (CB1/2R) partial agonist (−)-trans-Δ9- tetrahydrocannabinol (Δ9-THC) in Cannabis users trained to discriminate ingestion of Δ9-THC from ingestion of placebo [26]. However, this clinical result is inconsistent with preclinical findings that indicate a lack of cannabinoid-like DS effects for gabapentin in rats trained to discriminate another cannabinoid CB1/2R partial agonist, BAY 59-3074 [23]. There is currently no literature on the assessment of the binding affinity of gabapentin and other high-affinity ligands at the [3H] gabapentin-binding site for any cannabinoid receptor subtypes or endocannabinoid [e.g. anandamide and 2- arachidonoylglycerol (2-AG)] uptake enzymes. Δ9-THC [27,28] and BAY 59-3074 [29] have been reported to have substantial, high affinity for cannabinoid CB1 and CB2 receptor subtypes (Ki values: 15.3-55.4 nM). Δ9-THC also is known to exert potent action that is mediated through non-CB1/2R, cannabinoid G protein-coupled receptor 55 (GPR55) [30,31] that is expressed in human [32] and rat [33,34] brains while it is unknown whether BAY 59-3074 has actions at the cannabinoid GPR55. Importantly, cannabinoid GPR55 has been found to increase intracellular Ca2+ levels [31] and a recent in vitro study using a Bioluminescence Resonance Energy Transfer (BRET) assay demonstrated that cannabinoid GPR55 can form a heteromer with cannabinoid CB1R [34] in the rat striatum. In addition, another study identified a heteromer consisting of cannabinoid CB2R and GPR55 [35]. Considering the well-characterized effect of cannabinoid CB1R agonists as L-VDCC blockers [36-42] and the potential of gabapentin to serve as a functional L-VDCC blocker [13,19,20], the full Δ9-THClike DS effects of gabapentin in Cannabis users [26] might result from a blocking action of gabapentin and Δ9-THC at L-VDCCs.

In summary, it does appear pharmacologically important comprehensively to assess the L-VDCC-blocker- and cannabinoid-like DS effects of gabapentin and pregabalin for regulatory purposes. Further it may be important to assess whether gabapentin and pregabalin can enhance reinforcing and toxic effects of Δ9-THC and cannabinoid products. Given the clinical use of L-VDCC blockers against hypertension, such studies would also have significant impact on their safer use.


The present work was supported by the Division of Neurotoxicology/NCTR/U.S. FDA. The information in the present article is not a formal dissemination of information by the FDA and does not represent agency position or policy. The author thanks Dr. Merle G. Paule for comments on the preparation of the manuscript.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 8684
  • [From(publication date):
    February-2016 - Jul 17, 2018]
  • Breakdown by view type
  • HTML page views : 8529
  • PDF downloads : 155

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version